Bookmark
Forward
QuickView for Metaraminol (compound)
PubChem
| Name: | Metaraminol |
|---|---|
| PubChem Compound ID: | 164761 |
| Description: | A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION. |
| Molecular formula: | C13H19NO8 |
| Molecular weight: | 317.292 g/mol |
| Synonyms: |
962-82-3; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (-)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt); Benzyl alcohol, alpha-(1-aminoethyl)-m-hydroxy-, (-)-, (-)-tartrate (1:1); (-)-alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; 962-81-2
|
DrugBank
Identification
| Name: | Metaraminol |
|---|---|
| Name (isomeric): | DB00610 |
| Drug Type: | small molecule |
| Description: | A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION. |
| Synonyms: |
Metaraminolum [INN-Latin]; M-Hydroxypropadrine; Metaraminol Bitartrate; Metaraminolum [Latin]; M-Hydroxyphenylpropanolamine; M-Hydroxy Norephedrine; Hydroxynorephedrine; L-Metaraminol
|
| Brand: | Pressonex, Metaradrine, Aramine, Icoral B, Pressorol |
| Category: | Adrenergic alpha-Agonists, Adrenergic Agents, Sympathomimetics, Vasoconstrictor Agents |
| CAS number: | 54-49-9 |
Pharmacology
| Indication: | For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage |
|---|---|
| Pharmacology: |
Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complication...
show more » |
| Mechanism of Action: |
Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic & diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metarami...
show more » |
| Absorption: | The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection. |
| Protein binding: | Approximately 45% |
| Biotransformation: | Hepatic |
| Toxicity: | LD50=240 mg/kg (rat, oral); LD50=99 mg/kg (mouse, oral) |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
